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Abstract
Valve repair has emerged as an important intervention for the management
of bicuspid aortic valve disease. This systematic review aims to assess the
safety, efficacy and durability of bicuspid aortic valve repair. Initial searches
yielded 682 abstracts, reduced by de-duplication to 370, of which 56 full
papers were accessed and 30 met the inclusion criteria. Overall, 163 unique
outcomes for bicuspid aortic valve-preserving surgery were reported on 280
occasions. Bicuspid aortic valve-preserving surgery exhibited low operative
mortality (0.0-5.2%), excellent 5-year survival (82-100%) and 43-100% 5-year
freedom from reoperation. Bicuspid aortic valve repair is safe and efficacious,
but concerns regarding its durability necessitate further standardized outcome
assessments.
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Summary
Valve repair has emerged as an important intervention for the management of bicuspid aortic valve disease. This systematic review
aims to assess the safety, efﬁcacy and durability of bicuspid aortic valve repair. Initial searches yielded 682 abstracts, reduced by de-du-
plication to 370, of which 56 full papers were accessed and 30 met the inclusion criteria. Overall, 163 unique outcomes for bicuspid
aortic valve-preserving surgery were reported on 280 occasions. Bicuspid aortic valve-preserving surgery exhibited low operative mor-
tality (0.0–5.2%), excellent 5-year survival (82–100%) and 43–100% 5-year freedom from reoperation. Bicuspid aortic valve repair is safe
and efﬁcacious, but concerns regarding its durability necessitate further standardized outcome assessments.
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INTRODUCTION
The bicuspid aortic valve (BAV) is the most common congenital
cardiovascular abnormality, with a prevalence of 0.9–2.5% in the
general population [1, 2]. Aortic insufﬁciency (AI) (due to pro-
lapse or restriction) and stenosis (AS) are frequent complications,
with the peak incidence of AI occurring at 30 years and AS typ-
ically developing in the seventh decade [2, 3] (Fig. 1). The prox-
imal aorta is prone to dilatation and 50–60% of patients with
BAV will be affected [4]. The reasons for this are unclear, but it is
likely that underlying abnormalities in the aortic wall contribute
[5, 6]. Progressive aortic dilatation can lead to catastrophic
rupture or dissection, which is often fatal. The goals of surgical
intervention in patients with BAV are therefore aimed at correct-
ing aortic valve haemodynamics and managing the presence of
aortic aneurysm formation.
Treatment options for complicated BAV are diverse (Fig. 2).
Aortic valve replacement (AVR), with or without replacement of
the proximal aorta, is an effective intervention in patients with
AI or AS. However, mechanical valves require life-long anticoa-
gulation, and bio-prosthetic implants are associated with high
rates of degeneration and the need for revision surgery [7, 8].
The Ross procedure is an efﬁcacious option for young patients
with stenotic BAV because of proven durability, a low risk of
thromboembolism and beneﬁcial effects on long-term survival
[9]. The presence of AI and aortic dilatation, which are frequent-
ly seen in BAV, are however important risk factors for pulmon-
ary autograft failure [10, 11]. Novel valve-sparing techniques
have emerged as viable management options in patients with
BAV. These can be categorized broadly into interventions on
the AV itself and those aimed at repairing the proximal aorta,
although both procedures are often performed concurrently.
Procedures to repair the BAV include AV tricuspidisation, leaﬂet
resuspension, triangular resection, commissural plication, cir-
cumferential annuloplasty, pericardial patch repair for leaﬂet
perforation and pericardial extension valvuloplasty. When aortic
dilatation is also present, aortic root remodelling (Yacoub pro-
cedure), reimplantation (David procedure) or replacement is
also effective.
Studies of patients with tricuspid aortic valve (TAV) have high-
lighted a number of beneﬁts for preserving the native AV. These
include the avoidance of the haemorrhagic complications of
long-term anticoagulation and reduced rates of thromboembol-
ism, infective endocarditis (IE) and valvular degeneration com-
pared with AVR [12–14]. However, the longer duration of
ischaemic time may not be suitable for high-risk patients, and a
proportion of patients undergoing AV repair will require surgical
reintervention for progressive disease. At present, little work has
been carried out to assess the outcomes of AV repair and aortic
root interventions in patients with BAV. This systematic review
summarizes the perioperative, long-term and functional out-
comes of patients undergoing valve-sparing surgery on the BAV.
METHODS
Search strategy
The OVID SP versions of MEDLINE and EMBASE were searched
using terms for ‘aortic valve’, ‘bicuspid’ and ‘repair’ separated by
the Boolean operator ‘AND’ (Table 1). Additional search terms
captured articles pertaining to recognized AV-sparing procedures
(‘David’ and ‘Yacoub’ procedures). The study was limited to pub-
lications reporting outcomes for humans in English language,
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while no time limit was imposed. Reference lists and leading
journals were hand-searched for additional articles. All relevant
citations were collated using Reference Manager 12 (Thomson
Reuters, New York, NY, USA) and duplicates removed.
Study selection
The titles and abstracts of identiﬁed publications were screened
by one reviewer (R.N.W.) and checked by a second researcher
(H.A.V.). Included were publications reporting outcomes of BAV
repair. Thoracic aneurysm repair or procedures involving the
aortic root or ascending aorta were also included, provided the
native BAV was preserved. Excluded were studies solely of AVR,
articles where the outcomes of bicuspid and TAV surgery were
not presented independently and abstracts of conference pro-
ceedings (due to the high probability of missing data). Case
series were deﬁned as studies comprising a single group of parti-
cipants and cohort studies were those that compared two or
more different groups of participants. Full papers of potentially
Figure 1: Showing different aortic valve phenotypes: (A) normal tricuspid, (B) normal bicuspid, (C) stenosed bicuspid, (D and E) regurgitant bicuspid with
prolapsing cusp and (F) regurgitant bicuspid with restrictive cusp.
Figure 2: (A) Bioprosthetic aortic valve replacement, (B) modiﬁed Bentall procedure (with a Dacron graft sutured to a bioprosthesis; Bio-Bentall),
(C) remodelling procedure (white arrow showing tongue of graft to ﬁt scalloped sinus) and (D) reimplantation procedure (note dotted white arrow showing resus-
pension of cusp leaﬂets in this specimen).
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relevant studies were obtained and articles not meeting the eli-
gibility criteria were excluded.
Data extraction
The following data were extracted from included articles: (i) year
of publication; (ii) country in which the study was undertaken;
(iii) demographics of participants; (iv) study design; (v) the nature
of the interventions and comparators; and (vi) the impact of
the interventions on outcome measures (see Supplementary
Material). Where studies reported outcomes for both tricuspid
and bicuspid aortic valve surgery, only the endpoints for patients
with bicuspid aortic valves were extracted. All data were
recorded on a dedicated data extraction form and entered onto
a Microsoft Excel (Microsoft, Washington, DC, USA) spreadsheet
to facilitate data management and analysis. A second reviewer
(H.A.V.) checked the data extraction and any disagreements were
discussed with the senior author.
Data synthesis
The standard of outcome reporting was considered by calculat-
ing the proportion of endpoints that speciﬁed precisely when
they were measured. Outcome reporting was deemed to be of a
high standard when the time over which the endpoint was mea-
sured was reported (e.g. 30-day mortality, 5-year overall sur-
vival). Poor outcome reporting was deﬁned as failure to specify
the time period during which the outcome occurred (e.g. opera-
tive mortality, late death). Outcomes were divided into (i) peri-
operative outcomes, (ii) long-term morbidity and mortality and
(iii) functional and echocardiographic endpoints.
RESULTS
The search strategy (Table 1) yielded 682 abstracts, of which 370
remained after removal of duplicates (Fig. 3). A total of 56 full
papers were accessed and 29 of these fulﬁlled the eligibility cri-
teria. One further publication was identiﬁed through hand
searching of reference lists. Thirty articles were consequently
included in the review (Table 2) [4, 15–41]. These were published
between 1991 and 2011 in eight countries, including Germany
(n = 11), USA (n = 9) and Canada (n = 6). The majority of studies
were retrospective (n = 29), and there were 18 case series and 12
cohort studies. Twenty-ﬁve studies were of combined AV repair
and procedures on the aortic root or ascending aorta (replace-
ment, remodelling or reimplantation) [4, 14–22, 24–27, 29–31, 34,
35, 37–41], 5 reported outcomes of AV repair alone [23, 28, 32,
33, 36], 19 included only patients with BAV [4, 18, 19, 21–24,
27–29, 31–34, 36, 38–41] and a further 11 included patients with
both BAV and TAV [12, 14–17, 20, 25, 26, 30, 35, 37].+
Outcome reporting standard
A total of 163 different outcomes for valve-preserving BAV
surgery were reported on 280 occasions in the included studies.
The median number of outcomes reported in each study was
8.5 (range 1–22). The majority of endpoints were reported in
Table 1: Search terms used in the OVID SP versions
of MEDLINE and EMBASE
Search
criteria
Search terms
Medline 1. exp Aortic Valve/
2. exp Aortic Valve Insufficiency/
3. exp Aortic Valve Stenosis/
4. exp Aortic Aneurysm/
5. exp Aneurysm, Dissecting/
6. exp Cardiac Surgical Procedures/
7. exp Heart Valve Diseases/
8. aort$.tw adj3 (valv$.tw or steno$.tw or regurg$.tw
or insufficien$.tw or aneurysm.tw or dissect$.tw)
9. (aortic adj3 valve adj3 repair).tw
10. (aortic adj3 sparing adj3 root adj3 replacement).tw
11. or/1–10
12. bicuspid.tw
13. repair.tw
14. remodeling.tw
15. or/13–14
16. 11 and 12 and 15
17. (david adj3 procedure).tw
18. (yacoub adj3 procedure).tw
19. or/16–18
Embase 1. exp aortic valve repair/
2. exp aortic valve regurgitation/
3. exp aortic valve disease/
4. exp aorta valve/
5. exp heart valve surgery/
6. exp valvuloplasty/
7. exp aortic dissection/
8. exp aortic aneurysm/
9. aort$.tw adj3 (valv$.tw or steno$.tw or regurg$.tw
or insufficien$.tw or aneurysm.tw or dissect$.tw)
10. (aortic adj3 valve adj3 repair).tw
11. (aortic adj3 sparing adj3 root adj3 replacement).tw
12. or/1–11
13. bicuspid.tw
14. repair.tw
15. remodeling.tw
16. or/14–15
17. 12 and 13 and 16
18. (david adj3 procedure).tw
19. (yacoub adj3 procedure).tw
20. or/17–19
Figure 3: PRISMA diagram of studies considered for the systematic review.
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Table 2: Summary of included studies
Author, year and country Demographicsa Study design Outcomesa Resultsa
Aicher et al. (2004),
Germany [15]
n = 60
Male 83.3%
Mean age 53 ± 12 years
Aortic dissection 6.7%
Retrospective cohort study comparing valve-sparing aortic root
replacement in patients with TAV or BAV
In-hospital mortality
Postoperative AI grade
5-year overall survival
TE events/endocarditis during follow-up
Reoperation during follow-up
5-year mean AV gradient
5-year freedom from AI > II
5-year freedom from reoperation
0%
0.8 ± 0.7
82%
0%
1.7%
4.5 ± 2.3 mmHg
96%
98%
Aicher et al. (2007),
Germany [16]
n = 81
Male 85.2%
Aortic dissection 7.4%
AI > II 55.6%
Marfan 0%
Retrospective cohort study of aortic root remodelling in patients with
BAV, AI and dilatation of the ascending aorta. Comparison made with
patients with TAV
Hospital mortality
10-year overall survival
10-year freedom from AI > II
10-year freedom from reoperation
10-year freedom from AVR
0%
94%
87%
97%
99%
Aicher et al. (2010),
Germany [17]
n = 205 Retrospective cohort study comparing AV repair in patients with BAV
and TAV, limited raw data presented for BAV
5-year freedom from AI > II
10-year freedom from AI > II
86%
83%
Aicher et al. (2011), Germany [4] n = 316
Male 84.8%
Age range 3–79 years
Aortic dissection 8%
Severe AI 72.8%
Retrospective case series evaluating the effect of valve configuration on
outcomes after repair of BAV
In-hospital mortality
10-year overall survival
10-year freedom from AI > II
10-year freedom from reoperation
10-year freedom from AVR
0.63%
92%
81%
81%
84%
Alsoufi et al. (2005), Canada [18] n = 71
Male 87.3%
Mean age 41.5 ± 13.2 years
Retrospective case series of prospectively collected data on AV repair for
AI secondary to BAV, aortic remodelling/ replacement included
Hospital mortality
Postoperative AI > II
8-year overall survival
Freedom from TE/haemorrhage
8-year freedom from reoperation
8-year freedom from endocarditis
8-year freedom from AI > II
0%
0%
96.7%
100%
82.3%
90%
44.2%
Ashikhmina et al. (2010),
USA [19]
n = 108
Male 91%
Mean age 41 years
Retrospective case series of BAV repair. Patients with valve-sparing aortic
root replacements were excluded
In-hospital mortality
10-year overall survival
10-year freedom from reoperation
10-year freedom from AVR
0%
87%
64%
49%
Badiu et al. (2010), Germany [20] n = 11
Male 100%
Mean age 37 ± 15.8 years
Aortic dissection 0%
Marfan 0%
Retrospective cohort study comparing BAV and TAV repair for AI Operative mortality
5-year overall survival
5-year freedom from reoperation
5-year freedom from AI
5-year freedom from TE events
0%
100%
100%
57.1%
95.9%
Bakhtiary et al. (2009), Germany
[21]
n = 14
Male 92.9%
Mean age 58 ± 5 years
AI > I 78.6%
Retrospective case series of patients undergoing the modified David
procedure for incompetent BAV.
Endocarditis
NE
Operative death
In-hospital death
Late death
0%
0%
0%
0%
0%
Boodhwani et al. (2009),
Belgium [12]
n = 90 Retrospective cohort study comparing aortic valve repair for AI in BAV
and TAV, limited raw data presented for BAV
Comparison of freedom from AI recurrence
between BAV and TAV
P = 0.7
Continued
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Table 2: Continued
Author, year and country Demographicsa Study design Outcomesa Resultsa
Boodhwani et al. (2010),
Belgium [22]
n = 122
Male 92%
Mean age 44 ± 11 years
AI > II 86.1%
Retrospective case series of patients undergoing surgery for BAV in
association with either AI or dilatation of the proximal aorta
In-hospital mortality
Discharge AI < II
8-year overall survival
5-year freedom from AI > II
8-year freedom from AV reoperation
8-year freedom from AVR
8-year freedom from TE and bleeding
0%
93%
97 ± 2%
94 ± 3%
83 ± 5%
90 ± 5%
96 ± 2%
Casselman et al. (1999), USA [23] n = 94
Male 93%
Mean age 38 ± 10 years
Retrospective case series of aortic valve repair in patients with BAV and
AI
Immediate reoperation
Immediate postoperative AI > II
7-year freedom from AV reoperation
8.5%
2.1%
84%
Davierwala et al. (2003), Canada
[24]
n = 44
Mean age 39.3 ± 12.1 years
Male 93.2%
Preoperative CCF 13.6%
Retrospective cohort study of prospectively collected data comparing AV
repair to AVR in patients with AI caused by BAV. Procedures on the
aorta were included
Operative mortality
Late death
TE/Haemorrhagic events
5-year freedom from AI > I
5-year freedom from AV reoperation
0%
0%
0%
79 ± 8%
91 ± 5%
de Kerchove et al. (2009),
Belgium [25]
n = 54 Retrospective cohort study comparing the impact of preoperative AI on
outcome after aortic valve-sparing surgery, limited raw data presented
for BAV
5-year freedom from AI > II
8-year freedom from AV reoperation
98 ± 2%
91 ± 9%
Delius et al. (1998), USA [26] n = 16 Retrospective cohort study of aortic valve repair in patients with either
subvalvular or supravalvular aortic stenosis. Comparison made
between BAV and TAV
10-year overall survival
5-year freedom from reoperation
5-year freedom from AVR
100%
43%
43%
Doss et al. (2010), Germany [27] n = 66
(A) n = 49; (B) n = 17
Mean age 41.2 ± 12 years
(A) 58 years; (B) 39 yrs
Male 78.8%
(A) 82.3%; (B) 77.6%
AI > II 95.4%
(A) 82.3%; (B) 100%
Retrospective cohort study of (A) patch augmentation plus reduction
aortoplasty vs (B) modified David procedure in patients with BAV and
AI
5-year mortality
5-year reoperation
5-year endocarditis
5-year conduction disturbance/
thromboembolism/AI > I
(A) 2.0%
(B) 0%
(A) 2.0%
(B) 0%
(A) 2.0%
(B) 0%
(A) 0%
(B) 0%
Fraser et al. (1994), USA [28] n = 72
Male 94.4%
Mean age 39 ± 11 years
Retrospective case series of AV repair for AI secondary to BAV Operative death
Late death
3-year freedom from AV reoperation
0%
0%
89.5%
Kin et al. (2003), Japan [29] n = 19
Male 98%
Mean age 42 ± 17 years
Retrospective case series of AV repair for AI secondary to BAV, some
patients underwent concomitant procedures on the aorta
Hospital death
Early reoperation
Reoperation at follow-up
Late death
5-year overall survival
5-year freedom from AV reoperation
5.2%
5.2%
15.8%
5.2%
90 ± 7%
76 ± 23%
Lausberg et al. (2006),
Germany [30]
n = 89
n = 34; (B) n = 56
Retrospective cohort study comparing (A) AV repair alone to (B) AV
repair plus aortic root remodelling in patients with AI, limited data for
BAV alone
Freedom from significant AI in (A)
Freedom from reoperation in (A)
(A) 89.1%
(A) 100%
Mangini et al. (2010), Italy [31] n = 31
Mean age 49.9 ± 17.3 years
Male 83.9%
AI > I 96.8%
Prospective case series of patients undergoing repair of BAV for AI 30-day operative mortality
Discharge AI > I
5-year freedom from reoperation
3.2%
3.2%
96.6%
McMullan et al. (2007), Australia
[32]
n = 21
Median age 12.6 years
Mean follow-up 36.4 months
Retrospective cohort study of tricuspidisation with cusp extension vs
Ross procedure in children with AI or AS associated with BAV
Early reoperation
Endocarditis during follow-up
AVR during follow-up
AI > 2 during follow-up
9.5%
4.8%
9.5%
19.0%
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Minakata et al. (2004), USA [14] n = 54 Retrospective case series of AV repair for AI, limited raw data presented
for BAV
Reoperation during index admission
Reoperation during follow-up
5-year reoperation rate
3.7%
11.1%
9%
Moidl et al. (1995), Austria [33] n = 14
Mean age 30.9 ± 12 years
Male 92.9%
Preoperative AI grade 3.5 ± 0.1
Retrospective case series of valve-sparing correction of AI and BAV Reoperation during index admission 21.4%
Nash et al. (2004), USA [34] n = 77
Mean age 38 ± 10 years
Male 93%
Retrospective case series of the echocardiographic factors that predict
successful AV repair in patients with BAV and AI
AVR during index admission
Reoperation during index admission
Perioperative death
Thromboembolism
Endocarditis
2.6%
3.9%
0%
0%
0%
Odim et al. (2005), USA [35] n = 39 Retrospective case series of AV repair with pericardial leaflet extension Early mortality
2-year freedom from reoperation
2.6%
70–90%
Pretre et al. (2006), Switzerland
[36]
n = 12
Median age 18 years
Male 75%
Retrospective case series of AV repair with tricuspidization of the BAV Postoperative morbidity
AR > I
0%
8.3%
Rao et al. (2000), Canada [37] n = 23 Retrospective case series of AV repair for multiple pathologies, limited
raw data presented for BAV
Composite endpoint of reoperation or AI No difference
between BAV and
TAV (P > 0.05)
Schafers et al. (2000), Germany
[38]
n = 16
Age range 35–73 years
Male 75%
Aortic dissection 6.3%
Retrospective case series of AV repair and root replacement in patients
with BAV, AI and aortic dilatation
In-hospital mortality
AV reoperation during follow-up
Reoperation during follow-up
0%
0%
6.3%
Schafers et al. (2007), Germany
[39]
n = 173
Mean age 48 ± 16 years
Male 80.3%
Retrospective cohort study comparing (A) root remodelling, (B) AV
repair + supracommissural aortic replacement, (C) AV repair alone
In-hospital mortality
TE
Endocarditis
(A) 0%
(B) 2.6%
(C) 1.8%
0%
(A) 0%
(B) 0%
(C) 1.3%
Schafers et al. (2010), Germany
[40]
n = 153
Mean age 51 ± 12 years
Male 86.9%
Preoperative AI grade 2.6 ± 0.8
Aortic dissection 3.9%
Retrospective case series of valve-preserving root replacement for AI and
BAV
In-hospital mortality
10-year overall survival
10-year freedom from AI > I
10-year freedom from reoperation
10-year freedom from AVR
TE events
Endocarditis
10-year freedom from AV complications
0.7%
91%
90%
95%
97%
2.6%
0%
91%
Veldtman et al. (2006), USA [41] n = 21
Mean age 45 ± 12 years
Male 61.9%
Marfan 9.5%
AI > I 19.0%
Retrospective case series of aortic root repair or replacement with
preservation of the BAV
Perioperative death
Late death
Reoperation
0%
4.8%
9.5%
aWhere studies have included both patients with BAV and TAV repair, only demographics, outcomes and results of patients with BAV are reported.
AI: aortic insufficiency; AS: aortic stenosis; AV: aortic valve; AVR: aortic valve replacement; BAV: bicuspid aortic valve; CCF: congestive cardiac failure; TAV: tricuspid aortic valve; TE: thromboembolism.
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only one study (n = 127, 77.9%). The most frequently reported
endpoints were cardiopulmonary bypass time (CPB, n = 16,
53.3%), aortic cross clamp time (AXC, n = 16, 53.3%), 5-year
freedom from reoperation (n = 9, 30.0%), 5-year overall survival
(n = 7, 23.3%) and in-hospital mortality (n = 7, 23.3%). The timing
of outcome assessment was recorded precisely on 152 occasions
(54.3%).
Perioperative outcomes
Mortality in the early postoperative period was reported in 25
papers [4, 14–22, 24–26, 28–31, 34, 35, 37–41], although only 18
presented the results independently for patients with BAV [15–
22, 24, 28, 29, 31, 34, 35, 38–41]. Nine different terms were used
to describe mortality, including ‘in-hospital mortality’, ‘in-hospital
death’, ‘hospital mortality’, ‘hospital death’, ‘operative mortality’,
‘operative death’, ‘perioperative death’, ‘early mortality’ and
‘30-day operative mortality’. Mortality rates in patients undergo-
ing BAV procedures were generally good and ranged from 0 to
5.2% with a median of 0%. However, 5 studies failed to report
any mortality outcomes [23, 27, 32, 33, 36]. In addition, just one
study deﬁned precisely the time point at which early post-
operative mortality was measured [31].
Overall, 24 of the included publications reported the presence
or absence of early complications and 18 of these explicitly
described operative morbidity in patients with BAV. Six studies
did not document whether or not any complications of surgery
occurred [4, 19, 26, 35, 37, 41]. Early reoperation for bleeding was
documented in 14 studies and the incidence ranged from 0 to
21.4% [18, 21–23, 27–29, 32–34, 38–40]. The incidence of early
stroke or other neurological events was 0–6.3% and was
described in four studies [18, 21, 22, 38]. Arrhythmia is a
common complication of valve surgery, yet only 4 studies
recorded its presence, with an incidence of between 0 and
25.0% [28, 36, 38, 39]. Permanent pacemaker insertion was
reported in 2 articles and was necessary in 0.7–3.0% of patients
[22, 40]. Complications reported in one study included early IE
(0%), pulmonary embolism (2.3%), pericardial effusion (6.8%),
atrial ﬁbrillation (21.0%), myocardial infarction (0%) and pro-
longed ventilation (0%). Two articles also documented the inci-
dence of ‘operative complications’, which ranged from 0 to 9%,
although the exact nature of the complications was not speciﬁed
[20, 36].
Sixteen studies reported the duration of CPB and AXC: mean
pump times varied from 51 to 205 min and mean AXC values
ranged from 38 to 168 min. Six articles described the mean
length of hospital stay, and this varied from 5.5 to 13 days [24,
27, 28, 31, 36, 38]. The length of time spent on the intensive care
unit (mean duration range from 18 h to 3 days) was additionally
reported in 3 studies [21, 24, 31].
Long-term morbidity and mortality
Twenty-ﬁve publications provided at least one measure of
medium or long-term survival [4, 14–29, 32, 35, 37–41]. Fifteen of
these presented data exclusively for patients undergoing valve-
preserving BAV surgery [4, 15, 16, 18–22, 24, 26–29, 40, 41].
Overall survival was measured at a range of intervals, including
at 1, 3, 5, 8 and 10 years, while ﬁve publications reported ‘late
death’, although the time point at which this was measured was
not clearly deﬁned [21, 24, 28, 29, 41]. Overall survival rates at 1,
3, 5, 8 and 10 years were 93–99% (n = 2 publications), 87% (n = 1
publication), 82–100% (n = 7 publications), 97% (n = 2 publica-
tions) and 87–100% (n = 5 publications), respectively. The inci-
dence of ‘late death’ varied from 0 to 5.2%. One study reported
a 5-year mortality rate of between 0 and 2% [27].
The incidence of thromboembolic events during the follow-up
was recorded in seven studies [15, 18, 20, 22, 24, 27, 40]. Four of
these did not demonstrate any cases of late thromboembolism
[15, 18, 24, 27], while 3 reported incidences of between 2.6 and
4.1% [20, 22, 40]. Badiu et al. [20] also reported that freedom
from neurological events was 94% at 5 years postoperatively. The
incidence of postoperative IE of the BAV was described in ﬁve
publications and ranged from 0 to 10% [15, 18, 27, 32, 40],
although only 2 studies described precisely the timing of the
assessment of this outcome. Alsouﬁ et al. [18] reported 90%
freedom from IE at 8 years, while Doss et al. [27] described a 2%
incidence of IE at 5 years following surgery. Major haemorrhage
was described in three of the included articles. Freedom from
haemorrhagic complications was between 96 and 100% at time
intervals of up to 8 years [18, 22, 24]. Doss et al. [27] reported
that 0% of patients had conduction disturbance 5 years post
surgery.
The rate of reoperation was reported in 22 of the included
publications [4, 14–16, 18–20, 22–32, 35, 38, 40, 41]. The overall
reoperation rate for patients with BAV varied from 0 to 15.8%
during the follow-up period. Freedom from cardiac reoperation
was measured at 1, 2, 3, 5, 8 and 10 years, with the following
respective results: 96.8–98% (n = 2 publications), 70–90% (n = 1
publication), 98% (n = 1 publication), 43–100% (n = 9 publica-
tions), 82.3% (n = 1 publication) and 49–99% (n = 4 publications)
[4, 15, 16, 18–20, 26, 31, 35, 40]. Freedom from reoperation on
the AV (redo repair and/or replacement) was 94–95%, 89.5%, 87–
89.5%, 76–94%, 84, 91 and 83% at 1, 2, 3, 5, 7, 8 and 10 years
postprimary surgery, respectively [22–25, 28, 29]. Freedom from
AVR was also described in six articles. This was reported as 96,
43–99, 90 and 49–99% at 1, 5, 8 and 10 years, respectively [4, 16,
19, 22, 26, 40].
Echocardiographic and functional outcomes
The degree of AI in the immediate postoperative period was
reported in 11 publications [3–18, 18–24, 28, 29, 31, 33, 36, 38,
41]. The proportion of patients with AI grade >1 was between
0 and 8.3% [22, 24, 31, 36, 38, 41], while AI grade > 2 was less fre-
quently observed, with an incidence of between 0 and 2.1% [18,
23]. The mean early postoperative AI grade was noted in 3
studies to be between 0.39 and 1.1 [28, 29, 33]. Sixteen articles
reported the degree of AI present in the medium or long-term
follow-up period [4, 15–18, 20, 22, 24, 25, 27–30, 32, 33, 40]. This
was recorded in a variety of ways. Freedom from AI > 1 was 85%,
79–100 and 90% at 1, 5 and 10 years, respectively [24, 27, 40]. At
1, 3, 5, 8 and 10 years after surgery, the proportion of patients
with freedom from AI > 2 was reported as 94.7–98%, 96%,
71–98%, 44.2 and 81–87%, respectively [4, 15–18, 22, 25]. Badiu
et al. [20] described freedom from any grade of AI of 57.1% at 5
years following surgery, while Lausberg et al. [30] reported
89.1% freedom from signiﬁcant AI, although it is unclear how
this outcome was deﬁned. The mean follow-up AI grade was
reported in three studies and varied from 0.89 to 1.8 [28, 29, 33].
In addition, Boodhwani et al. [12] found no difference in the rate
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of recurrence of AI in patients with TAV and BAV. In a study by
Rao et al. [37], a composite endpoint of reoperation and/or AI
was measured, and again no differences were found between
patients with TAV or BAV.
Ten publications reported the gradient across the AV in the
early postoperative period [15, 21, 24, 26, 28, 31, 32, 34, 38, 41].
The mean AV gradient varied from 4.7 to 16 mmHg [15, 21, 28,
31, 34, 38, 41], while the peak AV gradient ranged from 16.2 to
28.7 mmHg [24, 26, 31, 34]. McMullan et al. [14] noted that 14.3%
of patients had an early postoperative peak AV gradient of
>20 mmHg. Four articles reported medium- to long-term AV
gradients [15, 18, 24, 27]. Values for the mean AV gradient were
between 3.8 and 9.6 mmHg [15, 18, 27], while peak gradients
ranged from 7.6 to 21 mmHg up to 5 years after initial surgery
[18, 24, 27]. The follow-up effective oriﬁce area of the AV was
reported in 2 studies with ﬁgures of 1.86–2.9 cm2 [18, 27].
The effects of BAV-sparing surgery on left ventricular ejection
fraction (LVEF) were commented on in four publications [18, 27,
29, 34]. Mean LVEF at hospital discharge was 50–55.8% [29, 34],
and this was maintained throughout the follow-up. Values for
the follow-up LVEF varied from 54.8–61.40% [27, 29], while
Alsouﬁ et al. [18] demonstrated that 5.6% of patients had
LVEF < 40% at the ﬁnal follow-up. Left ventricular end-diastolic
diameter (LVEDD) was 53.7–61.6 mm and decreased over time
to values of 52.8–55 mm at ﬁnal follow-up [29, 31, 33]. Left ven-
tricular end-systolic diameter (LVESD) also decreased with time
from 40.5–46.3 to 37.2–39.2 mm over the follow-up period [29,
33]. Five articles measured the postoperative NYHA classiﬁcation
of BAV patients [18, 22, 24, 28, 32]. Boodhwani et al. [22] reported
that on discharge from hospital, 85% of patients were NYHA
class I, 14% NYHA class II and 1% NYHA class III. In addition,
Fraser et al. [28] demonstrated that 6% of patients were NYHA
class II or worse at discharge. At ﬁnal follow-up, 2 studies noted
that 4.5–5.0% of patients were NYHA class III or IV [18, 24],
although McMullan et al. [32] documented that all patients were
asymptomatic (NYHA class I).
DISCUSSION
AI and AS are frequent complications of BAV anatomy. The prox-
imal aorta is also prone to dilatation, which can result in fatal
rupture or dissection. Surgical interventions aimed at correcting
these sequelae include AVR, the Bentall operation, the Ross pro-
cedure and AV repair with or without concomitant aortic proce-
dures (Fig. 2). AVR has proven effectiveness, although mechanical
valves require life-long anticoagulation and bio-prosthetic
implants are prone to degeneration requiring reoperation. The
Ross procedure is used mainly in young patients with predomin-
ant stenosis. However, progressive autograft dilatation has been
shown to occur in patients with previous BAV [42]. Although pre-
viously, AV repair has not been implemented as widely as rep-
arative procedures on the mitral or tricuspid valves, it has
emerged as a viable therapeutic alternative for patients with
complicated BAV. In order to ensure comprehensive uptake of
AV repair, it is ﬁrst necessary to demonstrate that operative tech-
niques are feasible and reproducible and have acceptable
efﬁcacy, safety and durability. This systematic review has sum-
marized all available outcomes for valve-preserving surgery on
the native BAV and has demonstrated that rates of perioperative
morbidity and mortality are low, with excellent long-term survival
and satisfactory freedom from reoperation. Echocardiographic
and functional endpoints have also been shown to be acceptable
both immediately after surgery and throughout follow-up.
Although it is beyond the scope of this review to systematical-
ly compare outcomes of BAV repair with those of AVR or pul-
monary autografts, it is useful to put some of the major ﬁndings
into context. Large series of patients undergoing AVR have
reported 5-, 8- and 13-year overall survival rates of 80–88%, 70–
81% and 31–53%, respectively [43–47]. These ﬁgures seem worse
than those identiﬁed in the present review, although patients
treated with AVR tend to be older and have more comorbidities
[48]. Overall survival was 82% at the 16-year follow-up in a large
cohort of patients undergoing the Ross procedure (median age
24 years) [49]. Freedom from reoperation in patients treated with
bio-prosthetic AVR has been shown to be 96%, 90–99% and 96%
at 5, 8 and 10 years, respectively, while mechanical AVR pros-
theses have even greater durability [43–47]. The 5- and 7-year
freedom from reoperation for pulmonary autograft failure are 93
and 91% [49, 50]. In patients requiring concomitant aortic
surgery, valve-sparing surgery may be a reason for a lower
freedom from reoperation compared with aortic root replace-
ment. These ﬁndings may give an impression that valve-sparing
BAV surgery is less durable than either AVR or the Ross proced-
ure. However, it must be borne in mind that AV repair is still in
its infancy in terms of operator experience at many centres and
reoperation ﬁgures are likely to improve considerably with time.
Hence, we strongly advocate that valve-sparing surgery in BAV
should exclusively be performed in most experienced centres
having a large aortic valve-sparing experience. Based on the
results of our review, it is necessary to fully inform the patient,
including making them aware of the longer operative time and
length of hospital stay and that it might be a safe alternative to
valve replacement in experienced high-volume centres.
Another potential beneﬁt of AV repair is that it leads to fewer
incidents of thromboembolism, IE and major haemorrhage.
Although there is some evidence to support this [12–14], a
review by Carr et al. [48] found that there was little difference
between AV repair, AVR and pulmonary autograft for these three
major complications. Further work is required to understand
better the relative safety of different aortic valve interventions,
and this should ideally be accomplished through a systematic
review and meta-analysis.
Our group advocates a systematic approach to BAV repair that
addresses both cusp and ascending aortic pathology and is tai-
lored to the speciﬁc anatomy encountered. We have demon-
strated that BAV repair is feasible, patients have excellent
long-term survival and repair durability remains acceptable at
mid-term with excellent freedom from late AV reoperation and
recurrent AI [12]. We have also shown that in the context of
valve-sparing surgery for BAV, root replacement is associated
with less AI recurrence compared with sub-commissural annulo-
plasty with or without ascending aortic replacement and the use
of a pericardial patch for raphe repair is associated with
increased recurrent AI [22]. Our approach is based on the prin-
ciple that BAV repair needs to address the cusps, functional
aortic annulus and the ascending aorta as one functional unit.
Root replacement in this setting is performed not only to
prevent the potentially fatal complications of aortic dissection
and rupture but also to stabilize the repair procedure. Ongoing
dilatation of the ventriculo-aortic junction (VAJ) or the sino-
tubular junction can induce recurrent AI and render the cusp
repair ineffective over the long-term. Thus, if a BAV repair is to
be attempted, an aggressive stance should be taken towards root
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replacement. We replaced the aortic root based on size criteria
and a visual assessment of the quality of the tissue of the aortic
wall. All patients with an aortic root size of >4.5 cm and some
patients with an aortic root diameter of <4.5 cm with fragile
aortic wall tissue undergo root replacement at our centre.
Another area of controversy relates to the use of a pericardial
patch for valve repair. In the adult patient, a patch may be used
for two reasons. First, for cusp restoration after the resection of a
restrictive or calciﬁed raphe. Secondly, to perform pericardial
cusp extension to help increase the coaptation surface of the
conjoint cusp by adding tissue to its free margin. The pericar-
dium, however, may become ﬁbrotic or calciﬁed with time,
leading to insufﬁciency, or the fact that these are complex valves
which require challenging repairs makes them more prone to
failure. The objective of cusp repair should be to attain uniform
cusp coaptation at approximately the mid-height of the sinuses
of Valsalva. It has been shown that the VAJ can dilate years after
sub-commissural annuloplasty. To this effect, we have demon-
strated that valve-sparing root replacement using the reimplanta-
tion technique can signiﬁcantly increase the durability of BAV
repair without additional morbidity when compared with
less-aggressive annuloplasty. This leads to lower immediate post-
operative transvalvular gradients when compared with the other
techniques. Despite criticisms of the non-physiological cusp
motion and potential cusp damage caused by the elimination of
the Valsalva sinuses, the reimplantation technique is associated
with excellent valve durability and long-term outcomes and the
combination of the type of graft and the techniques used actual-
ly can recreate the Valsalva sinuses shape and improve cusp
motion. In patients with recurrent AI requiring surgery after BAV
repair, the choice of rerepair vs replacement is not simply a
technical surgical decision, but also takes into account patient
age and co-morbidities and most importantly, the patients’
wishes regarding another attempt at repair. Since our under-
standing of the mechanism of failure in these patients has
improved, we increasingly offer rerepair using the reimplantation
technique to selected young patients.
The current review has also evaluated the standard of
outcome reporting in studies of BAV surgery by considering the
proportion of endpoints that were measured at clearly deﬁned
time points. Almost half of the endpoints reported (45.7%) did
not provide sufﬁcient information for the reader to ascertain the
timing of outcome assessment. This makes it extremely difﬁcult
to combine data from multiple studies in systematic reviews and
meta-analyses. To illustrate this problem, ‘late death’ was
reported by 5 studies in this review and none of these deﬁned
precisely when it was measured. The incidence of ‘late death’
also varied between 0 and 5.2%. ‘Late death’ of 0% at 10 years
postoperatively is a considerably better outcome than a 5.2%
chance of death at 1 year. In addition, overall survival was
reported at 1, 3, 5, 8 and 10 years, with different studies provid-
ing data at each time point. Heterogeneity in the timing of
outcome assessment is a signiﬁcant hindrance to data assimila-
tion, but is not the only problem with endpoint evaluation.
Different outcomes are invariably measured in studies of the
same disease, as emphasized by the ﬁnding that 163 unique
endpoints were reported in the publications included in this
review. In addition, outcomes with the same name may not be
deﬁned in the same way or even deﬁned at all. Although it was
beyond the scope of this review to consider comprehensively
endpoint deﬁnitions, it is interesting to note that there were 9
different terms used to describe early mortality after surgery.
A ﬁnal problem is outcome-reporting bias, which occurs when
individual endpoints are reported selectively on the basis of the
results, usually in favour of those that are signiﬁcant statistically
or against those that are negative. It is interesting to note that 5
articles included in this review (16.7%) failed to report any
measure of perioperative mortality and 6 did not state whether
complications occurred (20.0%). Although it is impossible to
speculate about morbidity and mortality in these series or the
reasons for their omission, it provides a useful illustration of how
missing data might affect the quality of evidence synthesis in sys-
tematic reviews. Many of these problems can be partially over-
come through the use of core outcome sets, which comprise
agreed sets of standardized endpoints reported, as a minimum,
in all studies of a given condition [51]. Although attempts have
been made to standardize deﬁnitions of perioperative mortality
in cardiac surgery [52], little work has considered other import-
ant endpoints, such as morbidity, reoperation or quality of life.
It is worthwhile considering that all of the publications
included in this review were either cohort studies or case series
and the vast majority was retrospective (96.7%). No randomized
trials (RCTs) or prospective observational studies were identiﬁed
comparing AV repair with either AVR or the Ross procedure.
Given the growing body of evidence supporting the use of valve-
sparing surgery as a viable alternative to valve-replacement
surgery in a select cohort of patients with BAV, further well-
designed prospective comparative studies are warranted. These
may be difﬁcult to undertake, not least because of the proven
efﬁcacy of valve replacement, a lack of equipoise amongst clini-
cians and problems with communicating trials and randomiza-
tion to patients. However, the recent success of the PARTNER
trial should encourage researchers to embark on RCTs in cardiac
surgery. Further work is also warranted to improve the quality of
outcome reporting in studies of AV surgery, possibly through the
development of a core outcome set. This will improve the reli-
ability and validity of the evidence synthesized in meta-analyses.
Another striking feature of this review is that no patient-reported
outcomes (PROs) were measured. Understanding the impact of
different surgical procedures on quality of life and satisfaction
with care from the patients’ perspective is invaluable for shared
decision-making when a range of treatment options exists.
Further work embedding PROs into prospective studies of AV
repair would be beneﬁcial.
This review should be interpreted in light of its limitations.
First, it did not systematically consider the evidence for AVR or
pulmonary autografts in patients with BAV, which would have
permitted a meta-analysis. However, it is the ﬁrst systematic
review to assess outcomes of valve-preserving surgery on the
BAV. Another best-evidence review has compared aortic remod-
elling and reimplantation, although studies of TAV were also
included and it was not conducted systematically [53]. A second
limitation is that the review was restricted to articles indexed in
MEDLINE and EMBASE and could have been expanded to
include other medical databases and ‘grey’ literature, although it
is unlikely that enough additional articles would have been iden-
tiﬁed to signiﬁcantly affect the ﬁndings.
In conclusion, the present review has shown that valve-
preserving surgery on the diseased BAV is feasible, safe and ef-
fective in both the short- and long-term. Some concerns exist
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regarding the durability of repairs and the need for reoperation,
although it is likely that these outcomes will improve as more
cardiac surgeons become more adept at performing AV repair.
The review has also highlighted concerns about the standard of
outcome reporting in studies of AV surgery and offers a partial
solution. With such favourable outcomes, it is likely that the use
of BAV repair will increase. Although the review goes some way
to understanding the current evidence base, further prospective
studies are warranted.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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